Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:ACST TSE:APS CVE:LTY TSE:REUN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti PharmaC$0.58+1.8%C$0.58C$0.47▼C$1.66C$18.19M1.226,576 shs2,450 shsAPSAptose BiosciencesC$2.33+5.9%C$2.31C$1.02▼C$2.59C$5.95M-1.3788183,913 shs5,800 shsLTYLiberty BiopharmaC$2.00+∞C$2.00C$0.06▼C$2.74C$21.54MN/A23,286 shs700 shsREUNReunion NeuroscienceC$0.00C$0.83▼C$6.56C$16.64M4.212,447 shs339 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%0.00%0.00%APSAptose Biosciences+5.91%+5.91%-0.85%+9.91%-2.92%LTYLiberty Biopharma0.00%0.00%0.00%0.00%0.00%REUNReunion Neuroscience0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti PharmaC$0.58+1.8%C$0.58C$0.47▼C$1.66C$18.19M1.226,576 shs2,450 shsAPSAptose BiosciencesC$2.33+5.9%C$2.31C$1.02▼C$2.59C$5.95M-1.3788183,913 shs5,800 shsLTYLiberty BiopharmaC$2.00+∞C$2.00C$0.06▼C$2.74C$21.54MN/A23,286 shs700 shsREUNReunion NeuroscienceC$0.00C$0.83▼C$6.56C$16.64M4.212,447 shs339 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%0.00%0.00%APSAptose Biosciences+5.91%+5.91%-0.85%+9.91%-2.92%LTYLiberty Biopharma0.00%0.00%0.00%0.00%0.00%REUNReunion Neuroscience0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma 0.00N/AN/AN/AAPSAptose Biosciences 2.00HoldN/AN/ALTYLiberty Biopharma 0.00N/AN/AN/AREUNReunion Neuroscience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaC$2.71M6.71C$0.93 per share0.63C$1.56 per share0.37APSAptose BiosciencesN/AN/AC$1.46 per share1.60C($13.59) per shareN/ALTYLiberty BiopharmaN/AN/AC$0.00 per share2,000.00C$0.79 per shareN/AREUNReunion NeuroscienceC$4.86M0.00N/AN/AC$1.82 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-C$10.54M-C$0.48N/AN/AN/A-455.58%-67.58%-8.25%N/AAPSAptose Biosciences-C$154.69M-C$10.41N/AN/AN/AN/A115.24%-136.29%N/ALTYLiberty BiopharmaN/A-C$0.16N/AN/AN/AN/AN/AN/AN/AREUNReunion Neuroscience-C$38.10M-C$3.30N/AN/AN/AN/A-86.35%-26.50%N/ALatest APS, LTY, ACST, and REUN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026APSAptose BiosciencesN/A-C$4.16N/A-C$4.16N/AN/A3/31/2026Q4 2025APSAptose BiosciencesN/A-C$4.07N/A-C$4.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/AAPSAptose BiosciencesN/A0.39%N/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/AREUNReunion NeuroscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A4.139.41APSAptose Biosciences-98.740.555.41LTYLiberty Biopharma8.190.120.12REUNReunion NeuroscienceN/A3.52N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma0.11%APSAptose Biosciences0.02%LTYLiberty BiopharmaN/AREUNReunion Neuroscience50.66%Insider OwnershipCompanyInsider OwnershipACSTAcasti Pharma20.28%APSAptose Biosciences17.11%LTYLiberty BiopharmaN/AREUNReunion Neuroscience34.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma3231.37 millionN/ANot OptionableAPSAptose Biosciences312.55 millionN/ANot OptionableLTYLiberty BiopharmaN/A10.77 millionN/ANot OptionableREUNReunion Neuroscience19011.72 millionN/ANot OptionableAPS, LTY, ACST, and REUN HeadlinesRecent News About These CompaniesReunion Neuroscience to Present Full Data from RECONNECT Phase 2 Clinical Trial at Upcoming ...May 12, 2026 | caledonianrecord.comCReunion Neuroscience to Present Full Data from RECONNECT Phase 2 Clinical Trial at Upcoming ASCP and APA Annual MeetingsMay 11, 2026 | globenewswire.comLuvesilocin Designated Breakthrough Therapy for Postpartum DepressionFebruary 23, 2026 | empr.comEU.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation StatusFebruary 23, 2026 | markets.businessinsider.comReunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) at ACNP Annual MeetingJanuary 20, 2026 | markets.businessinsider.comReunion Neuroscience expands Series A to $133m after positive trial milestonesSeptember 16, 2025 | finance.yahoo.comAbbVie wagers more than $1B on Gilgamesh’s psychedelic drugAugust 25, 2025 | biopharmadive.comBReunion’s psychedelic prodrug reduces postpartum depression symptoms in ph. 2 studyAugust 18, 2025 | fiercebiotech.comFSome postpartum moms are using psychedelics — experts say they may be onto somethingAugust 1, 2025 | msn.comReAlta Life Sciences Names Ellen Lubman as Chief Business OfficerJuly 28, 2025 | contractpharma.comCReAlta Life Sciences Strengthens Management Team with the Appointment of Biotechnology Business Leader Ellen Lubman, MBA as Chief Business OfficerJuly 28, 2025 | finance.yahoo.comPsychedelics may improve psychotherapy outcomes, but obstacles remainJuly 3, 2025 | healio.comHShares of psychedelics biotech nearly double on depression dataFebruary 3, 2025 | biopharmadive.comB5 More Things We Learned from the "Love Is Blind" ReunionNovember 10, 2024 | psychologytoday.comPRx Rundown: AstraZeneca, Danco Laboratories, GSK and moreOctober 11, 2024 | mmm-online.comMOasis Bringing 2025 Reunion Tour To North AmericaSeptember 30, 2024 | spin.comSWhy are so many Roman statues headless?August 26, 2024 | msn.comTopics in Integrative NeuroscienceAugust 23, 2024 | cambridge.orgCCT’s younger generations are really worried about climate change. They’re doing something about it.August 12, 2024 | courant.comCVisual NeuroscienceAugust 3, 2024 | cambridge.orgCMedia Sentiment Over Time Top HeadlinesView All HeadlinesAs Small-Cap Outperformance Continues, These 2 ETFs Provide ExposureBy Jessica Mitacek | May 21, 2026The Power Grid Is Dying—Is It Time to Buy Its Replacement?By Jeffrey Neal Johnson | May 15, 2026Palomar’s High-Risk Insurance Strategy Is Paying Off BigBy Peter Frank | May 29, 2026Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?By Jessica Mitacek | June 1, 20263 Ways to Play the Data Center Land GrabBy Nathan Reiff | May 31, 2026APS, LTY, ACST, and REUN Company DescriptionsAcasti Pharma CVE:ACSTC$0.58 +0.01 (+1.75%) As of 03/27/2023Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.Aptose Biosciences TSE:APSC$2.33 +0.13 (+5.91%) As of 06/9/2026 03:56 PM EasternAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Liberty Biopharma CVE:LTYC$2.00 +2.00 (+∞) As of 10/10/2018Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.Reunion Neuroscience TSE:REUNReunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
